

1 **The impact of immune history and variant on SARS-CoV-2 viral kinetics and infection re-**  
2 **bound**

3  
4 James A. Hay<sup>1\*</sup>, Stephen M. Kissler<sup>1\*</sup>, Joseph R. Fauver<sup>2,3\*</sup>, Christina Mack<sup>4\*</sup>, Caroline  
5 G. Tai<sup>4</sup>, Radhika M. Samant<sup>4</sup>, Sarah Connolly<sup>4</sup>, Deverick J. Anderson<sup>5</sup>, Gaurav Khullar<sup>6</sup>,  
6 Matthew MacKay<sup>6</sup>, Miral Patel<sup>6</sup>, Shannan Kelly<sup>6</sup>, April Manhertz<sup>6</sup>, Isaac Eiter<sup>6</sup>, Daisy  
7 Salgado<sup>6</sup>, Tim Baker<sup>6</sup>, Ben Howard<sup>6</sup>, Joel T. Dudley<sup>6</sup>, Christopher E. Mason<sup>6</sup>, Manoj Nair<sup>7</sup>,  
8 Yaoxing Huang<sup>7</sup>, David D. Ho<sup>7</sup>, Nathan D. Grubaugh<sup>2\*\*</sup>, Yonatan H. Grad<sup>1\*\*</sup>

9  
10 \* These authors contributed equally.

11 \*\* Co-senior authors.

12  
13

14 1 Harvard T.H. Chan School of Public Health, Boston, MA

15 2 Yale School of Public Health, New Haven, CT

16 3 University of Nebraska Medical Center, Omaha, NE

17 4 IQVIA, Real World Solutions, Durham, NC

18 5 Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC

19 6 TEMPUS Labs, Chicago, IL

20 7 Columbia University Vagelos College of Physicians and Surgeons, New York, NY

21

22 Correspondence and requests for materials should be addressed to:

23 Email: [ygrad@hsph.harvard.edu](mailto:ygrad@hsph.harvard.edu)

24 Telephone: 617.432.2275

25

26 Funding Statement: Supported in part by CDC contract 200-2016-91779, Emergent  
27 Ventures at the Mercatus Center, the Huffman Family Donor Advised Fund, the MorrisSinger  
28 Fund, the National Basketball Association, and the National Basketball Players  
29 Association.

30

31 Data availability: All code and data required to reproduce the analyses are available at  
32 <https://github.com/gradlab/SC2-kinetics-immune-history>.

33 **Abstract**

34

35 The combined impact of immunity and SARS-CoV-2 variants on viral kinetics during infections  
36 has been unclear. To address this gap, we characterized 2,964 infections in the National Basket-  
37 ball Association occupational health cohort. Over half remained potentially infectious (cycle  
38 threshold (Ct)<30) five days post detection, with minimal differences by variant and vaccination  
39 history. Only 7/1032 infections (0.7%) showed viral rebound, defined as 3+ days with Ct<30 fol-  
40 lowing an initial clearance of 3+ days with Ct≥30. Pre-booster antibody titers and symptoms pre-  
41 dicted peak viral RNA and clearance rates. Boosted individuals with Omicron BA.1 infections were  
42 more likely to have low pre-booster antibody titers and cleared their infections more slowly than  
43 non-boosted individuals. Since booster vaccination protects against infection, these longer clear-  
44 ance times suggest viral clearance takes longer in individuals with less infection protection. The  
45 shifting landscape of viral kinetics underscores the need for continued monitoring to optimize  
46 clinical and public health interventions.

47

48 **Introduction**

49 The viral kinetics of SARS-CoV-2 underlie the epidemiology of COVID-19 and the policies sur-  
50 rounding infection control. The amount and duration of viral shedding influences infectiousness(1–  
51 6) and the duration of test positivity affect isolation policies, test recommendations, and clinical  
52 care guidelines.(7–13) Descriptions of viral kinetics are also important for establishing baselines  
53 to measure the effectiveness of antiviral drugs. For example, rebounds of viral RNA concentra-  
54 tions and symptoms have been observed after antiviral treatment, but it has been unclear to what  
55 extent such rebounds also occur in the absence of drug.(14, 15) Most longitudinal viral kinetics  
56 studies pre-date the emergence of the BA.1 lineage, which features dramatic antigenic diver-  
57 gence from prior lineages, as well as the rollout of third and fourth vaccine doses.(16, 17) Early  
58 findings on viral kinetics therefore need to be updated to account for extensive and heterogeneous  
59 immune experience across the population.(18, 19)

60  
61 To characterize the viral kinetics of SARS-CoV-2 infection, including rebounds, for the Delta and  
62 Omicron (BA.1 lineages BA.1.1529 and BA.1.1) variants in symptomatic and asymptomatic indi-  
63 viduals with varied vaccination and infection histories, we measured viral RNA levels using  
64 densely-sampled RT-qPCR tests from 2,964 SARS-CoV-2 infections, each taken by combined  
65 anterior nares and oral swabs, that occurred between 7<sup>th</sup> July, 2020, and 26<sup>th</sup> January, 2022, prior  
66 to the detection of BA.2.12.1, BA.4 and BA.5, or the regular detection of BA.2, in this cohort. As  
67 a proxy for immune response to SARS-CoV-2, we used antibody titers against the ancestral  
68 SARS-CoV-2 (WA1) strain spike protein measured prior to the administration of booster doses,  
69 but predominantly after primary vaccination.

70  
71 We interpreted the data in two ways. First, we estimated the probability of an individual having a  
72 PCR cycle threshold (Ct) value less than 30, as a proxy for infectiousness, on each day post  
73 detection using a logistic regression model. Second, we estimated the peak viral RNA concentra-  
74 tions, viral RNA proliferation rate, and viral RNA clearance rate across variants and immune sta-  
75 tuses using a semi-mechanistic model. Our findings provide key estimates for the duration and  
76 magnitude of viral RNA shedding in the upper respiratory tract and its variation across symptom  
77 status, variants, immune states, and individuals.

## 78 **Data**

79 We identified 2,964 distinct infections from 2,678 individuals in this cohort (**Supplementary Fig-**  
80 **ure 1**). By the time of their final test, 2,410 (90.0%) individuals had one detected infection, 261  
81 (9.74%) had two detected infections, 5 (0.19%) had three detected infections, and 1 (0.04%) had  
82 four detected infections. A total of 593 infections were detected within one day of a prior negative  
83 PCR test result, and thus the timing of the onset of test positivity can be assumed with reasonable  
84 accuracy. We defined these infections as the “frequent testing” group. The remaining 2,371 infec-  
85 tions were detected two days or more from a previous negative test result or were detected with  
86 no prior negative test in the dataset. These were predominantly tests following suspected expo-  
87 sure, recent symptom onset, or periodic clearance for occupational health requirements, and thus  
88 we consider this latter group of detections as a reasonable proxy for infection detection in the  
89 absence of frequent testing, which is the case for most populations. We define these infections  
90 as the “delayed detection” group.

91  
92 Of 1,086 infections with known symptom status, 766 reported symptoms at some point during the  
93 infection (70.5%). Individuals in the delayed detection group were more likely to be symptomatic  
94 than in the frequent testing group (73.1% vs. 64.9%; Chi-squared test statistic = 5.09; p-value  
95 <0.05). Most symptomatic individuals were detected around the time of symptom onset (**Supple-**  
96 **mentary Figure 2**; median delay from detection to symptom onset of zero days (N=553) in the  
97 delayed detection group and one day (N=171) in the frequent testing group). Symptom onset  
98 preceded the peak measured Ct value by a median of two days (N=550) in the delayed detection  
99 group and three days (N=171) in the frequent testing group (**Supplementary Figure 3**).

100  
101 Based on genome sequencing, 1561 infections were confirmed to be Omicron (1 BA.2.10 isolate,  
102 the rest were lineages within BA.1), 266 confirmed to be Delta, and 268 confirmed as other line-  
103 ages. An additional 868 infections were not sequenced; however, due to the rapid replacement  
104 of the circulating lineage in this cohort, we classified many of these as suspected Delta or other  
105 lineages based on the dominant lineage at time of detection (**Supplementary Figure 4**). We  
106 excluded non-sequenced samples following the detection of Omicron BA.1 due to the continued,  
107 albeit low-level, detection of Delta.

## 108 **Interpersonal variation in viral RNA trajectories**

109 Viral trajectories varied substantially across individuals regardless of lineage (**Figure 1A**). Most  
110 individuals (65.6%, 95% CrI: 62.2-68.8%) in the frequent testing group remained potentially infec-  
111 tious, defined as having a Ct<30, on day 5 post detection. This fraction decreased to 19.4% (95%  
112 CrI: 16.8-22.3%) at day 10. In the delayed detection group, fewer individuals remained potentially  
113 infectious at days 5 and 10, likely because they were detected later in their infection. In this group,  
114 the probability of having a Ct<30 was 50.5% (95% credible interval (CrI): 47.9-53.1%) on day 5  
115 post detection and 9.49% (95% CrI: 8.16-11.0%) on day 10.

## 116 **Incidence of rebounds**


117  
118 We next characterized the frequency of rebound viral RNA trajectories in this cohort. Viral re-  
119 bounds may be characterized by the duration of the “quiescent” period of low viral concentration  
120 between distinct peaks, the duration of the subsequent rebound, and the timing of rebound onset  
121 relative to infection, but no consensus definition of viral rebound based on these quantities exists.  
122 We defined rebound as any viral trajectory with a decline in Ct value to <30 for 3+ days of tests  
123 (the rebound) after 3+ days of tests with Ct≥30 or a negative result (the quiescent period) following  
124 an initial Ct value <30 (the first detection of infection). Testing often ceased following initial clear-  
125 ance, and thus to minimize the impact of right censoring we only considered those trajectories  
126 with at least 3+ days of tests with negative or Ct≥30 following a Ct value <30 as the denominator  
127 (N=1,032). We detected seven viral rebounds under this definition. Less stringent definitions led  
128

129 to more rebound classifications. For example, 40 (2.91%) of 1,360 infections were identified as  
130 rebounds when only 2+ consecutive days of Ct $\geq$ 30 followed by 2+ days of Ct $<$ 30 was required to  
131 be classified as such (**Table 1; Figure 1B**). All individual-level viral trajectories classified as re-  
132 bounds under this less stringent definition are shown in **Supplementary Figure S5**. Under this  
133 definition, we found that rebound infections were more likely in Omicron BA.1 infections, with 36  
134 (4.10%; N=877) Omicron BA.1 infections resulting in rebound compared to one (0.536%; N=190)  
135 and three (1.02%; N=293) Delta and other infections, respectively (**Supplementary Table 1**; Chi-  
136 squared test for Omicron BA.1 (N=877) vs. non-Omicron BA.1 infection (N=483), test statistic =  
137 10.6, p-value < 0.05). Similarly, we found that rebounds were more common in boosted individu-  
138 als, with 32 (6.48%; N=494) rebounds in boosted individuals vs. three (0.923%; N=325) and two  
139 (1.24%; N=161) rebounds in vaccinated and unvaccinated individuals, respectively (**Supplemen-**  
140 **tary Table 2**; Chi-squared test for boosted (N=494) vs. not-boosted (N=902) infection, test statis-  
141 tic = 29.7, p-value < 1e-7).  
142

143 **Table 1. Number of rebound infections classified under different definitions for initial clearance and**  
 144 **subsequent rebound.**  
 145

Initial clearance duration (consecutive days with Ct $\geq$ 30)	Rebound duration (days above Ct value threshold)	Ct value threshold of rebound	Rebounds	Total	Percentage
$\geq 4$	$\geq 4$	Ct<30	0	787	0.00%
$\geq 4$	$\geq 3$	Ct<30	1	787	0.13%
$\geq 4$	$\geq 2$	Ct<30	4	787	0.51%
$\geq 3$	$\geq 4$	Ct<30	2	1032	0.19%
$\geq 3$	$\geq 3$	Ct<30	7	1032	0.68%
$\geq 3$	$\geq 2$	Ct<30	16	1032	1.55%
$\geq 2$	$\geq 4$	Ct<30	7	1360	0.52%
$\geq 2$	$\geq 3$	Ct<30	18	1360	1.32%
$\geq 2$	$\geq 2$	Ct<30	40	1360	2.94%
$\geq 4$	$\geq 4$	Ct<25	0	787	0.00%
$\geq 4$	$\geq 3$	Ct<25	0	787	0.00%
$\geq 4$	$\geq 2$	Ct<25	0	787	0.00%
$\geq 3$	$\geq 4$	Ct<25	1	1032	0.10%
$\geq 3$	$\geq 3$	Ct<25	1	1032	0.10%
$\geq 3$	$\geq 2$	Ct<25	2	1032	0.19%
$\geq 2$	$\geq 4$	Ct<25	1	1360	0.07%
$\geq 2$	$\geq 3$	Ct<25	2	1360	0.15%
$\geq 2$	$\geq 2$	Ct<25	5	1360	0.37%

146



147  
 148 **Figure 1. PCR Ct value trajectories for confirmed and suspected infections. (A)** PCR Ct value trajec-  
 149 tories for each acute Delta (red), Omicron BA.1 (blue), and other (black) infection. Individuals are grouped  
 150 by the gap between detection and their most recent negative or inconclusive PCR test (Frequent testing  
 151 vs. Delayed detection). Thick lines depict the mean Ct value over time, counting negative tests as Ct=40.  
 152 Thin lines depict individual level Ct values over time. The horizontal dotted lines mark Ct=30, which we  
 153 consider here as a proxy for possible infectiousness and antigen test positivity. **(B)** Subsets of PCR Ct  
 154 value trajectories that were classified as rebounds, stratified by testing frequency group. Rebounds are  
 155 defined here as any trajectory with an initial Ct value <30, followed by a sequence of two or more consec-  
 156 utive negative tests or tests with Ct value  $\geq 30$ , and subsequently followed by two or more consecutive tests  
 157 with Ct value <30.

158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199


### **Minimal differences across variants and vaccination histories in the probability of having low Ct values over time**

To assess differences in the duration of test positivity and infectiousness by variant and immune status, we modeled the probability of an individual having  $Ct < 30$  on each day post detection. As a baseline model, we fitted a logistic regression model with a smoothing spline on days since detection as a predictor. We compared various models with or without variant and vaccination history based on  $k$ -fold cross-validation and Bayesian model averaging.

The best-performing model used days since detection, stratified by both the cumulative number of previous exposures (infection or vaccination) and virus lineage, to predict the time course of low Ct values. The models including only vaccination status and lineage or days since previous exposure and lineage also performed well (**Supplementary Table 3 and 4**). This indicates that the interpersonal variation in low Ct values over time is better captured by models that account for exposure history than by models that account for time since detection alone. However, the difference in classification accuracy between the models was small. The baseline model, which included only the number of days since detection as a predictor, gave an overall classification accuracy for an individual having  $Ct < 30$  or  $\geq 30$ /negative of 81.7% with an AUC of 88.7% (group-level classification accuracies:  $Ct < 30 = 59.2\%$ ;  $Ct \geq 30$ /negative = 89.4%) for the frequent testing group, and an overall classification accuracy of 84.1% with an AUC of 90.4% ( $Ct < 30 = 72.5\%$ ;  $Ct \geq 30$ /negative = 87.7%) in the delayed detection group. In contrast, the best model, which included the cumulative number of exposures and virus lineage in addition to days since detection, gave an overall classification accuracy of 82.9% with an AUC of 90.0% ( $Ct < 30 = 63.7\%$ ;  $Ct \geq 30$ /negative = 89.4%) for the frequent testing group and an overall classification accuracy of 84.8% with an AUC of 91.3% ( $Ct < 30 = 69.6\%$ ;  $Ct \geq 30$ /negative = 89.6%) in the delayed detection group. These results indicate that while exposure histories help to explain mean viral RNA kinetics, they provide little assistance in predicting an individual's course of infectiousness over time, due to a high degree of individual-level variation, which may be contributed by stochastic effects or other unmeasured characteristics.

Vaccination provides multiple layers of protection against SARS-CoV-2, leading to reduced rates of infection<sup>(20)</sup> and faster clearance of the virus.<sup>(19)</sup> Consistent with these findings, individuals who received two vaccine doses prior to infection with pre-Delta and pre-Omicron variants ( $N=17$ ) cleared to negative results or high Ct values faster than unvaccinated individuals ( $N=216$ ) (**Supplementary Figure 6**). While boosting reduced rates of infection in our cohort,<sup>(20)</sup> boosted individuals with Omicron BA.1 infections ( $N=651$ ) tended to sustain low Ct values for longer durations than individuals who had only undergone an initial vaccine course ( $N=251$ ), defined as either two doses of an mRNA vaccine or a single dose of the Ad.26.COVS adenovirus vector-based vaccine (**Figure 2A; Supplementary Figure 6**). This pattern was robust to refitting the model after excluding player infections, resulting in a subpopulation more representative of the general population in age and health status (**Supplementary Figure 7**). We also found similar patterns after subsetting infections by their symptom status (**Supplementary Figure 8**).





200  
 201 **Figure 2. (A)** Proportion of confirmed and suspected Omicron BA.1 infections with Ct<30 on each day post  
 202 detection by vaccination status and detection group. Solid colored lines and shaded ribbons depict posterior  
 203 estimates from a generalized linear model predicting probability of Ct<30 as a function of days since detec-  
 204 tion, vaccination status and variant, showing the posterior mean (solid line) and 95% credible intervals  
 205 (shaded ribbon) of each conditional effect. Dotted horizontal and vertical lines mark 5% probability and day  
 206 5 post detection, respectively. **(B)** As in (A), but additionally stratified by single point-in-time anti-spike  
 207 antibody titer against the ancestral SARS-CoV-2 (WA1) strain as measured by the Diasorin Trimeric Assay.  
 208 **(C)** Distribution of antibody titers (colored points) stratified by variant and vaccination status of each de-  
 209 tected infection, with mean titers (large black points) and bootstrapped 95% confidence intervals for the  
 210 mean (horizontal lines). Grey bars are histograms of antibody titer counts in bins of 10 arbitrary units  
 211 (AU)/ml. Note that stratification is by infection and not individual, and that antibody titers were measured at  
 212 a single point in time rather than near the time of infection. The Diasorin Trimeric Assay values are truncated  
 213 between 13 and 800 AU/ml.

214  
 215

216 **Pre-Omicron antibody titer explains variation in viral RNA clearance**

217 To assess the mechanisms behind the unexpected slower clearance in boosted Omicron BA.1  
218 infections, we assessed viral kinetics stratified by antibody titer. In addition to exposure history  
219 information, 979 individuals were tested at least once (1,107 measurements total) with the Di-  
220 asorin Trimeric Assay for antibody titers against the spike protein from the ancestral SARS-CoV-  
221 2 (WA1) strain (**Supplementary Figure 9**). Most titers were obtained from mid-September to mid-  
222 October 2021, and thus we consider these titers to represent an individual's post primary vac-  
223 cination course response rather than post-boost/post-Omicron infection immunity (**Supplemen-  
224 tary Figure 10**). The median time between the most recent vaccine dose and the titer draw was  
225 162 days (interquartile range: 129–180 days) (**Supplementary Figure 11**).

226  
227 We hypothesized that these single point-in-time SARS-CoV-2 antibody titer measurements rep-  
228 resented a proxy of the strength of the immune response to SARS-CoV-2 and thus would be  
229 reflected in the features of viral kinetics over the course of infection. A total of 494 measurements  
230 were classified as low antibody titers ( $\leq 250$  arbitrary units [AU]/ml) and 523 as high titers ( $> 250$   
231 AU/ml). This cutoff was chosen as a conservative upper bound for defining risk of Delta infection  
232 (see **Materials & Methods**). Most individuals either had very low titers ( $< 13$  AU/ml) or titers at the  
233 upper limit of detection (800 AU/ml) of the assay (**Figure 2C**).

234  
235 We fitted a logistic regression model for the probability of having a  $Ct < 30$  on each day since  
236 detection, stratified by the interaction of an individual's booster status and their pre-booster anti-  
237 body titer status (**Figure 2B**; **Supplementary Figure 12**). Boosted individuals with a low antibody  
238 titer had the highest and longest duration of  $Ct < 30$  over time since detection in both the frequent  
239 testing and delayed detection group. In the delayed detection group, individuals with low antibody  
240 titers were more likely to have  $Ct < 30$  than individuals with high antibody titers regardless of  
241 booster status, though boosted individuals with high antibody titers maintained  $Ct < 30$  for longer  
242 than non-boosted individuals with low titers. To account for potential confounding from waning  
243 immunity, in which low titers simply represent a longer time since previous exposure, we restricted  
244 the dataset to include only individuals who had their titer measured within 100-200 days after a  
245 previous exposure. We also repeated the analysis after restricting to only infections detected 60-  
246 90 days following an antibody titer measurement. These trends were maintained in both subsets  
247 (**Supplementary Figure 13**).

248  
249 Based on these findings, we hypothesized that boosted individuals who nevertheless were in-  
250 fected with Omicron BA.1 may have had relatively poor BA.1-specific immune responses to prior  
251 SARS-CoV-2 exposures, leading to uncharacteristically long infections. To test this hypothesis,  
252 we stratified each infection by vaccination status and variant and compared antibody titers be-  
253 tween these groups (**Figure 2C**). Antibody titers were lower among fully vaccinated individuals  
254 who were subsequently infected with Delta than individuals who had been infected with a pre-  
255 Delta variant. This suggests that individuals with a high antibody titer at around the time of Delta  
256 circulation were less likely to be infected with Delta. In contrast, we found that mean antibody  
257 titers among Omicron BA.1-infected, fully vaccinated individuals were similar to individuals in the  
258 pre-Delta, unvaccinated group, suggesting that higher titer individuals were not substantially less  
259 likely to be infected than lower titer individuals. Finally, we found that antibody titers were lowest  
260 among Omicron BA.1 infected boosted individuals, suggesting that individuals with a high titer  
261 measurement prior to being boosted were less likely to have Omicron BA.1 infections.


262  
263

264 **The effect of immune status and variant on viral proliferation, peak viral RNA titers, and**  
265 **clearance**

266 We next adapted a framework to estimate the impact of antibody titer, vaccination status, and  
267 variant on peak viral RNA concentrations, proliferation phase duration, and clearance duration  
268 (**Figure 3**).<sup>(10, 19)</sup> According to the viral kinetic model, and among Omicron BA.1 infections,  
269 boosted individuals had a longer estimated viral clearance time than non-boosted individuals (8.1  
270 days (95% CrI: 7.8-8.5) vs. 6.1 days (95% CrI: 5.7-6.5), respectively), in line with the results from  
271 the logistic regression model. Viral proliferation times and peak viral RNA were similar among  
272 boosted and non-boosted individuals with Omicron BA.1 infections (**Supplementary Table 5**).  
273 When stratifying by post-initial vaccination antibody titer, Delta infections featured a consistently  
274 higher peak viral RNA than Omicron BA.1 infections. Among Omicron BA.1 infections, high anti-  
275 body titers were associated with faster viral clearance times and lower peak viral RNA. Prolifera-  
276 tion times were similar across variants and titers (**Supplementary Table 6**).

277  
278 Finally, we fitted the viral RNA kinetic model to Omicron BA.1 infections after stratifying individuals  
279 based on their symptom status as well as vaccination status or antibody titer group. We found the  
280 same pattern of longer clearance times for boosted individuals relative to fully vaccinated individ-  
281 uals, with symptomatic boosted individuals demonstrating longer clearance times than asympto-  
282 matic boosted individuals (**Supplementary Table 7**). Presence of symptoms was associated with  
283 higher peak viral RNA, especially among those with low antibody titer (**Supplementary Table 8**).  
284 Presence of symptoms was also associated with longer clearance times.

285



286  
287 **Figure 3. Estimated viral trajectories by variant and titer.** Points depict measured Ct values, lines depict  
288 the estimated population mean viral trajectories, and shaded regions depict the 95% credible intervals for  
289 the estimated population viral trajectories. A) Non-Delta and non-Omicron infections in individuals who were  
290 previously unexposed (no prior record of vaccination or infection), B) Delta infections with titer ≤ 250, C)  
291 Delta infections with titer > 250, D) Omicron infections with titer ≤ 250, E) Omicron infections with titer >  
292 250. Peak viral loads were higher for Delta infections than for Omicron infections when stratifying by titer (i  
293 and ii), and titers ≤ 250 were associated with higher viral loads when stratifying by variant (iii and iv). Low  
294 titers were also associated with longer clearance times (v and vi).

## 295 Discussion

296 We found that individuals infected with SARS-CoV-2 often had Ct values <30 beyond the five-day  
297 isolation period following SARS-CoV-2 infection currently recommended by the CDC.(21) This  
298 finding is in line with other studies measuring Ct values from upper respiratory tract samples, the  
299 duration of antigen test positivity, and the duration of infectious viral load.(4, 22–24) While we do  
300 not have data on infectiousness by day to clarify the exact link between Ct and infectiousness,  
301 nearly half of the individuals in this cohort had potentially infectious viral loads (Ct<30) five days  
302 after their initial detection, even in those detected later in their infection course (25). By day 10,  
303 the number of individuals with Ct<30 was substantially reduced but still high. The duration of  
304 positivity was highly variable across individuals, and low Ct values consistent with potential infec-  
305 tiousness were sometimes maintained for up to two weeks. These observations suggest the use  
306 of test-based, rather than time-based, protocols for defining the duration of isolation to limit the  
307 spread of SARS-CoV-2.

308  
309 Rebounds with recurrence of symptoms and positive rapid antigen tests after a period of negative  
310 test results have been increasingly reported in individuals treated with SARS-CoV-2 antiviral  
311 drugs,(14, 15) but estimates for the frequency of viral rebounds in the absence of antiviral treat-  
312 ment have been lacking. Among infected boosted individuals in this cohort, who were predomi-  
313 nantly infected with Omicron BA.1, we detected seven rebounds in viral trajectory, stringently  
314 defined as any Ct value trajectory with at least 3 consecutive days of negative tests or tests with  
315 Ct≥30 after the initial peak followed by 3 or more consecutive days with Ct<30. However, more  
316 rebounds were detected when using less stringent Ct value-based definitions and were more  
317 frequent in Omicron-infected or boosted individuals, occurring in ~6% of infections in contrast to  
318 ~1% of infections in the pre-booster pre-Omicron phase of the pandemic. It was not routine for  
319 testing to continue following suspected clearance in this cohort, and thus these results may rep-  
320 resent a lower bound on the incidence of rebound infections. The frequency of viral trajectory  
321 rebounds depends on the definition of ‘rebound’, highlighting the need for standardized definitions  
322 to enable comparisons across studies. We did not measure the recurrence of culturable virus  
323 during these resurgent low Ct periods, and thus further work is needed to understand if viral RNA  
324 rebounds are a reliable proxy for infectivity. Moreover, we did not have sufficient information to  
325 define rebounds with respect to clearance and recurrence of symptoms, though the experience  
326 of the occupational health team is that rebounds of a clinical nature have been extremely rare,  
327 with only one documented case.(26) Overall, these findings suggest that symptom monitoring  
328 after clearing isolation may be warranted, and a return to isolation may be necessary for individ-  
329 uals with rebound infections.(15)

330  
331 Boosted individuals in this cohort were less likely to be infected with Omicron BA.1,(20) and those  
332 who had a breakthrough infection tended to have a low antibody titer measurement to the WA1  
333 spike protein after their initial vaccine course. In this context, test positivity following Omicron BA.1  
334 infection lasted longer for boosted individuals than for non-boosted individuals, regardless of  
335 symptom status. This observation was further supported by a viral kinetic model that found longer  
336 clearance times for Omicron BA.1 infections in boosted relative to non-boosted individuals. More-  
337 over, high antibody titers to the WA1 spike protein were associated with lower peak viral RNA  
338 concentrations and faster clearance times for both Delta and Omicron BA.1 infections. Together,  
339 these results suggest that the low antibody titers in infected boosted individuals conferred in-  
340 creased risk for infection as well as slower control and clearance of infection.

341  
342 An important limitation of this study is that the cohort is not representative of the general popula-  
343 tion, as it is predominately male, young, and includes professional athletes. However, our key  
344 findings were preserved in analyses after excluding the players. We did not test for the presence  
345 of infectious virus, and our findings are based on Ct values obtained from combined nasal and

346 oropharyngeal swabs.(4) While low Ct values have been associated with potential infectiousness  
347 and antigen test positivity,(27–30) this is an imperfect proxy. It is possible that some infections  
348 were undetected, and thus the reported number of prior infections should be interpreted as a  
349 lower bound for each member of the cohort. SARS-CoV-2 antibody titers were only measured  
350 from mid-September to mid-October 2021 and were taken at varying time points after initial vac-  
351 cination course (between 0 and 290 days), so we could not assess the relationship between an-  
352 tibody waning and viral kinetics. Antibody titers were measured against the spike protein of the  
353 WA1 lineage, which correlate poorly with protection against the antigenically distinct Omicron  
354 lineages; thus, it is unclear how these data are associated specifically to Omicron-immunity, be-  
355 yond representing a proxy for overall immune response.

356  
357 Variants and immune statuses interact, sometimes in unexpected ways, to produce viral kinetics  
358 that differ in duration and intensity. Collecting longitudinal viral load data in more diverse cohorts  
359 will help to ensure that isolation and quarantine policies are based on the best available evidence  
360 and will help to properly contextualize results from ongoing drug and vaccine trials. Similarly, our  
361 findings suggest that SARS-CoV-2 control measures may be better informed by measurements  
362 of immune status than proxies such as number or timing of receipt of vaccine doses or of infec-  
363 tions. Testing this hypothesis will require widespread collection and analysis of serological, infec-  
364 tion, and vaccination data in diverse cohorts and broader availability of quantitative antibody tests  
365 designed for the spike protein of Omicron lineages.  
366

## 367 **Methods**

368

### 369 **Study design**

370 The data reported here represent a convenience sample including team staff, players, arena staff,  
371 vendors, and others affiliated with the NBA as described previously.(10, 19) The retrospective  
372 study includes samples collected between 7th July 2020 and 26th January 2022 (**Supplementary**  
373 **Figure 1**). Clinical samples were obtained by combined swabs of the anterior nares and orophar-  
374 ynx, collected separately from each anatomical site, for each patient administered by a trained  
375 provider. Daily testing was required for most individuals prior to vaccination availability, with less  
376 frequent testing but close monitoring required after vaccination. Cycle threshold (Ct) values were  
377 generated using the Roche cobas target 1 assay. For the viral kinetics model analyses, Ct values  
378 were converted to viral genome equivalents using a standard curve.(10)

379

380 We classified all individuals as having Ct value  $<30$  or not on each day post-detection. This thresh-  
381 old was chosen based on a combination of antigen sensitivity and studies of virus culture by Ct,  
382 where the presence of culturable virus is often assumed to correlate with infectivity.(27, 28, 31–  
383 33) We stratified infections by those who had a negative or inconclusive test  $\leq 1$  day prior to de-  
384 tection and those whose last negative or inconclusive test was  $\geq 2$  days ago. We assumed that  
385 individuals testing negative at the end of an acute infection remained negative for the remainder  
386 of the study period, whereas those ending in a positive test are right-censored. Rebound trajec-  
387 tories were defined as any trajectory with a sequence of two or more consecutive Ct values  $\geq 30$   
388 or negative tests after the initial peak followed by two or more consecutive Ct values  $<30$ . We  
389 considered more stringent definitions both for initial clearance (3+ or 4+ days of Ct  $\geq 30$  or negative  
390 test following initial peak) and subsequent rebound (3+ or 4+ days of Ct  $< 30$ ). In some instances,  
391 individuals were tested multiple times per day and thus for ease of model fitting we excluded  
392 3,757 positive or inconclusive and 14,709 negative samples from repeat tests on the same day in  
393 our analyses, prioritizing the earliest test and then lowest Ct value test on each day.

394

395 Vaccination information was reported and verified by NBA staff and a clinical operational team.  
396 828 individuals had been boosted by the time of their last PCR test, 529 had completed their  
397 primary vaccination course (two doses of an mRNA vaccine or one dose of Janssen /  
398 Ad.26.COVS adenovirus vector-based vaccine), 8 had received one vaccine dose, and 13 con-  
399 firmed to be unvaccinated. The vaccination statuses of the remaining individuals were unknown.  
400 The time course of individual vaccination and exposure times is shown in **Supplementary Figure**  
401 **10**.

402

### 403 **Study oversight**

404 In accordance with the guidelines of the Yale Human Investigations Committee, this work with de-  
405 identified samples was approved for research not involving human subjects by the Yale Institu-  
406 tional Review Board (HIC protocol # 2000028599). This project was designated exempt by the  
407 Harvard Institutional Review Board (IRB20-1407).

408

### 409 **Classification of infections**

410 We tagged each series of positive tests buffered by at least 14 days of negative or missing tests  
411 on each side as a distinct infection. After an infection was flagged, subsequent positives were not  
412 classified as a new infection for 90 days. Isolated positive tests with no other positive within 14  
413 days either side were not considered as detections. We track the cumulative number of exposures  
414 (defined as either receiving a vaccination or infection) over time. Individuals who received the  
415 Janssen/Ad.26.COVS adenovirus vector-based vaccine were counted as having received two  
416 vaccine doses. 351 additional infections were reported to the program outside of the main testing  
417 regime, either through an external PCR or rapid antigen test, or from a positive antibody test result

418 (not including the Diasorin Trimeric Assay results described below). We consider these detections  
419 as contributing towards an individual's infection history but are unable to include them in the Ct  
420 value trajectory analyses.

421

### 422 **Genome sequencing and lineage assignment**

423 RNA was extracted and confirmed as SARS-CoV-2 positive by RT-qPCR.(34) Next Generation  
424 Sequencing was performed with the Illumina COVIDSeq ARTIC viral amplification primer set (V4,  
425 384 samples, cat# 20065135). Library preparation was performed using the amplicon-based Illu-  
426 mina COVIDseq Test v033 and sequenced 2×74 on Illumina NextSeq 550 following the protocol  
427 as described in Illumina's documentation. The resulting FASTQs were processed and analyzed  
428 on Illumina BaseSpace Labs using the Illumina DRAGEN COVID Lineage Application;(35) ver-  
429 sions included are 3.5.0, 3.5.1, 3.5.2, 3.5.3 and 3.5.4. The DRAGEN COVID Lineage pipeline was  
430 run with default parameters recommended by Illumina. Lineage assignment and phylogenetics  
431 analysis using the most updated version of Pangolin(36) and NextClade(37), respectively. All se-  
432 quenced Omicron infections were lineage BA.1 apart from 1 BA.2.10 infection. Sequenced Delta  
433 infections were a combination of lineages B.1.617.2 and AY.x.

434

435 There were 5 and 482 non-sequenced infections in the window of time when Alpha was replaced  
436 by Delta (29<sup>th</sup> May 2021 to 18<sup>th</sup> July 2021) and after the first detection of Omicron BA.1 (3<sup>rd</sup> De-  
437 cember 2021 onwards), respectively (**Supplementary Figure 4**). We removed these 483 infec-  
438 tions from variant-specific analyses and assigned all non-sequenced infections prior to the detec-  
439 tion of Omicron BA.1 to the dominant lineage at the time of detection (i.e., all infections prior to  
440 29<sup>th</sup> May 2021 were assumed "Other" and all infections between 18<sup>th</sup> July 2021 and 3<sup>rd</sup> December  
441 2021 were assumed "Delta"). We removed all non-sequenced infections detected after 3<sup>rd</sup> De-  
442 cember 2021 from variant-specific analyses rather than classifying them as Omicron BA.1 due to  
443 the continued presence of Delta. Omicron BA.2 was not regularly detected until after this period,  
444 with only 1 confirmed BA.2 infection (BA.2.10), which was removed from these analyses.

445

### 446 **Antibody titers**

447 Individuals were tested with the Diasorin Trimeric Assay for IgG antibody titers against the ances-  
448 tral SARS-CoV-2 (WA1) strain spike protein during the 2021 pre-season period (September-Oct-  
449 ober 2021). The majority (>90%) of blood draws were from mid-September to early October 2021.  
450 We classified individuals with a titer of >250 AU/ml as being in the high titer group and in the low  
451 titer group otherwise, chosen based on its correlation with authentic virus neutralization results  
452 for wildtype and Delta.(38, 39) Specifically, an authentic virus neutralization titer of 100 was found  
453 to be well correlated with a 50% protective neutralization level for wildtype(40) and found to cor-  
454 respond to a DiaSorin AU of 189.09 (95%CI: 147.61-235.75) (**Supplementary Figure 14**). The  
455 cutoff of 250 was therefore chosen as a conservative upper bound classifying an individual as at  
456 lower risk of infection with Delta or wildtype SARS-CoV-2. Note that this cutoff does not predict  
457 infection risk with Omicron and was simply chosen as a proxy for an individual's immune compe-  
458 tence.

459

### 460 **Logistic regression models**

461 We used the RStan package *brms* to fit Bayesian logistic regression models estimating the prob-  
462 ability of having Ct value <30 on each day post detection, stratified by detection speed.(41) As a  
463 baseline, we considered a model without variant-specific effects, using smoothing splines to esti-  
464 mate the probability of having a Ct value less than 30 on each day post detection. We then fitted  
465 additional logistic regression models, adding an additional effect for vaccination status, cumula-  
466 tive number of previous exposures or days since previous exposure, and/or lineage. We then  
467 ranked models based on the expected log predictive density calculated using *k*-folds cross-vali-  
468 dation (25 folds) and evaluated their classification accuracy and area under the receiver operator



469 curve. For the antibody titer analyses, we fitted Bayesian logistic regression models for the prob-  
470 ability of Ct value <30 as a function of days since detection, stratified by the interaction of titer  
471 group (above or below 250 AU/ml), lineage and vaccination status. Further details on the fitting  
472 process can be found in the **Supplementary Methods**.

473

#### 474 **Viral kinetic model**

475 We extended a previously reported model for capturing SARS-CoV-2 viral kinetics to estimate the  
476 viral proliferation time, viral clearance time, and peak viral load by variant and immune status.(10,  
477 19) The model approximates viral kinetics on a logarithmic scale as a piecewise linear function,  
478 corresponding to an exponential increase of virus followed by an exponential clearance at possi-  
479 bly different rates. To estimate the relationship between booster status and viral kinetics, we first  
480 stratified the model by (1) Omicron boosted and (2) Omicron non-boosted individuals. There were  
481 too few boosted individuals who were infected with other variants to reliably fit the model to non-  
482 Omicron infections. Next, to estimate the relationship between antibody titer and viral kinetics, we  
483 stratified the model by (1) Delta infections with titer  $\leq 250$ , (2) Delta infections with titer  $> 250$ , (3)  
484 Omicron infections with titer  $\leq 250$  (4) Omicron infections with titer  $> 250$ , and finally (5) non-Delta  
485 and non-Omicron infections in individuals who had not had any prior exposure either through  
486 infection or vaccination, to serve as a baseline. Full details on the fitting procedure may be found  
487 in (10, 19) and the **Supplementary Methods**.

## 488 References

- 489 1. A. Marc, M. Kerioui, F. Blanquart, J. Bertrand, O. Mitjà, M. Corbacho-Monné, M. Marks, J.  
490 Guedj, Quantifying the relationship between SARS-CoV-2 viral load and infectiousness.  
491 *Elife*. **10** (2021), doi:10.7554/ELIFE.69302.
- 492 2. O. Puhach, K. Adea, N. Hulo, P. Sattonnet, C. Genecand, A. Iten, F. J. Bausch, L. Kaiser,  
493 P. Vetter, I. Eckerle, B. Meyer, Infectious viral load in unvaccinated and vaccinated individu-  
494 als infected with ancestral, Delta or Omicron SARS-CoV-2. *Nat. Med.*, 1–1 (2022).
- 495 3. M. Marks, P. Millat-Martinez, D. Ouchi, C. h. Roberts, A. Alemany, M. Corbacho-Monné, M.  
496 Ubals, A. Tobias, C. Tebé, E. Ballana, Q. Bassat, B. Baro, M. Vall-Mayans, C. G-Beiras, N.  
497 Prat, J. Ara, B. Clotet, O. Mitjà, Transmission of COVID-19 in 282 clusters in Catalonia,  
498 Spain: a cohort study. *Lancet Infect. Dis.* **21**, 629–636 (2021).
- 499 4. R. Ke, P. P. Martinez, R. L. Smith, L. L. Gibson, A. Mirza, M. Conte, N. Gallagher, C. H.  
500 Luo, J. Jarrett, R. Zhou, A. Conte, T. Liu, M. Farjo, K. K. O. Walden, G. Rendon, C. J.  
501 Fields, L. Wang, R. Fredrickson, D. C. Edmonson, M. E. Baughman, K. K. Chiu, H. Choi, K.  
502 R. Scardina, S. Bradley, S. L. Gloss, C. Reinhart, J. Yedetore, J. Quicksall, A. N. Owens, J.  
503 Broach, B. Barton, P. Lazar, W. J. Heetderks, M. L. Robinson, H. H. Mostafa, Y. C.  
504 Manabe, A. Pekosz, D. D. McManus, C. B. Brooke, Daily longitudinal sampling of SARS-  
505 CoV-2 infection reveals substantial heterogeneity in infectiousness. *Nature Microbiology*  
506 *2022 7:5. 7*, 640–652 (2022).
- 507 5. K. Sun, W. Wang, L. Gao, Y. Wang, K. Luo, L. Ren, Z. Zhan, X. Chen, S. Zhao, Y. Huang,  
508 Q. Sun, Z. Liu, M. Litvinova, A. Vespignani, M. Ajelli, C. Viboud, H. Yu, Transmission heter-  
509 ogeneities, kinetics, and controllability of SARS-CoV-2. *Science*. **371** (2021),  
510 doi:10.1126/SCIENCE.ABE2424/SUPPL\_FILE/ABE2424\_SUN\_SM.PDF.
- 511 6. R. Ke, C. Zitzmann, D. D. Ho, R. M. Ribeiro, A. S. Perelson, In vivo kinetics of SARS-CoV-2  
512 infection and its relationship with a person's infectiousness. *Proceedings of the National*  
513 *Academy of Sciences*. **118**, e2111477118 (2021).
- 514 7. B. J. Quilty, S. Clifford, J. Hellewell, T. W. Russell, A. J. Kucharski, S. Flasche, W. J. Ed-  
515 munds, K. E. Atkins, A. M. Foss, N. R. Waterlow, K. Abbas, R. Lowe, C. A. B. Pearson, S.  
516 Funk, A. Rosello, G. M. Knight, N. I. Bosse, S. R. Procter, G. R. Gore-Langton, A. Shower-  
517 ing, J. D. Munday, K. Sherratt, T. Jombart, E. S. Nightingale, Y. Liu, C. I. Jarvis, G. Medley,  
518 O. Brady, H. P. Gibbs, D. Simons, J. Williams, D. C. Tully, S. R. Meakin, K. Zandvoort, F.  
519 Y. Sun, M. Jit, P. Klepac, M. Quaife, R. M. Eggo, F. G. Sandmann, A. Endo, K. Prem, S.  
520 Abbott, R. Barnard, Y. W. D. Chan, M. Auzenberg, A. Gimma, C. J. Villabona-Arenas, N.  
521 G. Davies, Quarantine and testing strategies in contact tracing for SARS-CoV-2: a model-  
522 ling study. *The Lancet Public Health*. **6**, e175–e183 (2021).
- 523 8. D. B. Larremore, B. Wilder, E. Lester, S. Shehata, J. M. Burke, J. A. Hay, M. Tambe, M. J.  
524 Mina, R. Parker, Test sensitivity is secondary to frequency and turnaround time for COVID-  
525 19 screening. *Science Advances*. **7**, eabd5393 (2021).
- 526 9. C. D. Mack, E. B. Wasserman, M. E. Killerby, R. H. Soelaeman, A. J. Hall, A. MacNeil, D. J.  
527 Anderson, P. Walton, S. Pasha, E. Myers, C. S. O'Neal, C. J. Hostler, N. Singh, T. Mayer,  
528 A. Sills, Results from a Test-to-Release from Isolation Strategy Among Fully Vaccinated  
529 National Football League Players and Staff Members with COVID-19 - United States, De-  
530 cember 14-19, 2021. *MMWR Morb. Mortal. Wkly. Rep.* **71**, 299–305 (2022).

- 531 10. S. M. Kissler, J. R. Fauver, C. Mack, S. W. Olesen, C. Tai, K. Y. Shiue, C. C. Kalinich, S.  
532 Jednak, I. M. Ott, C. B. F. Vogels, J. Wohlgemuth, J. Weisberger, J. DiFiori, D. J. Anderson,  
533 J. Mancell, D. D. Ho, N. D. Grubaugh, Y. H. Grad, Viral dynamics of acute SARS-CoV-2 in-  
534 fection and applications to diagnostic and public health strategies. *PLoS Biol.* **19**, e3001333  
535 (2021).
- 536 11. A. Singanayagam, S. Hakki, J. Dunning, K. J. Madon, M. A. Crone, A. Koycheva, N. Der-  
537 qui-Fernandez, J. L. Barnett, M. G. Whitfield, R. Varro, A. Charlett, R. Kundu, J. Fenn, J.  
538 Cutajar, V. Quinn, E. Conibear, W. Barclay, P. S. Freemont, G. P. Taylor, S. Ahmad, M.  
539 Zambon, N. M. Ferguson, A. Lalvani, A. Badhan, S. Dustan, C. Tejpal, A. V. Ketkar, J. S.  
540 Narean, S. Hammett, E. McDermott, T. Pillay, H. Houston, C. Luca, J. Samuel, S. Bre-  
541 mang, S. Evetts, J. Poh, C. Anderson, D. Jackson, S. Miah, J. Ellis, A. Lackenby, Commu-  
542 nity transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vac-  
543 cinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.  
544 *Lancet Infect. Dis.* **22**, 183–195 (2022).
- 545 12. J. Hellewell, T. W. Russell, R. Beale, G. Kelly, C. Houlihan, E. Nastouli, A. J. Kucharski, Es-  
546 timating the effectiveness of routine asymptomatic PCR testing at different frequencies for  
547 the detection of SARS-CoV-2 infections. *BMC Medicine* 2021 19:1. **19**, 1–10 (2021).
- 548 13. N. N, L. G, L. H. Q, G. J, E. I, L. Q, G. A, F. V, H. C, P. Jc, T. V, M. J, M. B, B. K, L. Fx, T.  
549 Jf, F. E, P. J, C. C, R. F, K. A, E. M, R. Jc, T. P, G. D, L. M. V, B. D, T. C, D. X, Y. Y, M. F,  
550 L. C, V. B, G. J, Modeling SARS-CoV-2 viral kinetics and association with mortality in hos-  
551 pitalized patients from the French COVID cohort. *Proc. Natl. Acad. Sci. U. S. A.* **118** (2021),  
552 doi:10.1073/PNAS.2017962118.
- 553 14. Boucau, Uddin, Marino, Regan, Choudhary, Flynn, Chen, Stuckwisch, Mathews, Liew,  
554 Singh, Reynolds, Iyer, Chamberlin, Vyas, Vyas, Turbett, Li, Lemieux, Barczak, Siedner, Vi-  
555 rologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for  
556 COVID-19. *medRxiv*, doi:10.1101/2022.05.24.22275326.
- 557 15. M. Charness, J. Strymish, V. A. Boston, H. System, E. Adams, D. Lindy, D. Ho, Rapid Re-  
558 lapse of Symptomatic Omicron SARS-CoV-2 Infection Following Early Suppression with  
559 Nirmatrelvir/Ritonavir (2022), doi:10.21203/rs.3.rs-1588371/v3.
- 560 16. S. Lusvarghi, S. D. Pollett, S. N. Neerukonda, W. Wang, R. Wang, R. Vassell, N. J. Epsi, A.  
561 C. Fries, B. K. Agan, D. A. Lindholm, C. J. Colombo, R. Mody, E. C. Ewers, T. Lalani, A.  
562 Ganesan, E. Goguet, M. Hollis-Perry, S. A. Coggins, M. P. Simons, L. C. Katzelnick, G.  
563 Wang, D. R. Tribble, L. Bentley, A. E. Eakin, C. C. Broder, K. J. Erlandson, E. D. Laing, T.  
564 H. Burgess, E. Mitre, C. D. Weiss, SARS-CoV-2 BA.1 variant is neutralized by vaccine  
565 booster-elicited serum, but evades most convalescent serum and therapeutic antibodies.  
566 *Sci. Transl. Med.* (2022), doi:10.1126/SCITRANSLMED.ABN8543.
- 567 17. K. van der Straten, D. Guerra, M. J. van Gils, I. Bontjer, T. G. Caniels, H. D. G. van Willi-  
568 gen, E. Wynberg, M. Poniman, J. A. Burger, J. H. Bouhuijs, J. van Rijswijk, A. H. A. Lavell,  
569 B. Appelman, J. J. Sikkens, M. K. Bomers, A. X. Han, B. E. Nichols, M. Prins, H. Vennema,  
570 C. Reusken, M. D. de Jong, G. J. de Bree, C. A. Russell, D. Eggink, R. W. Sanders, Map-  
571 ping the antigenic diversification of SARS-CoV-2. *medRxiv*, 2022.01.03.21268582 (2022).
- 572 18. M. Cevik, M. Tate, O. Lloyd, A. E. Maraolo, J. Schafers, A. Ho, SARS-CoV-2, SARS-CoV,  
573 and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a sys-  
574 tematic review and meta-analysis. *The Lancet Microbe.* **2**, e13–e22 (2021).

- 575 19. S. M. Kissler, J. R. Fauver, C. Mack, C. G. Tai, M. I. Breban, A. E. Watkins, R. M. Samant,  
576 D. J. Anderson, J. Metti, G. Khullar, R. Baitz, M. MacKay, D. Salgado, T. Baker, J. T. Dud-  
577 ley, C. E. Mason, D. D. Ho, N. D. Grubaugh, Y. H. Grad, Viral Dynamics of SARS-CoV-2  
578 Variants in Vaccinated and Unvaccinated Persons. *N. Engl. J. Med.* **385**, 2489–2491  
579 (2021).
- 580 20. C. G. Tai, L. L. Maragakis, S. Connolly, J. DiFiori, D. J. Anderson, Y. H. Grad, C. D. Mack,  
581 Association Between COVID-19 Booster Vaccination and Omicron Infection in a Highly  
582 Vaccinated Cohort of Players and Staff in the National Basketball Association. *JAMA*  
583 (2022), doi:10.1001/jama.2022.9479.
- 584 21. Website, (available at [https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-](https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html)  
585 [isolation.html](https://www.cdc.gov/coronavirus/2019-ncov/your-health/quarantine-isolation.html)).
- 586 22. E. Landon, A. H. Bartlett, R. Marrs, C. Guenette, S. G. Weber, M. J. Mina, High rates of  
587 rapid antigen test positivity after 5 days of isolation for COVID-19. *bioRxiv* (2022), ,  
588 doi:10.1101/2022.02.01.22269931.
- 589 23. B. Lefferts, I. Blake, D. Bruden, M. B. Hagen, E. Hodges, H. L. Kirking, E. Bates, A. Hoeldt,  
590 B. Lamont, S. Saydah, A. MacNeil, M. G. Bruce, I. D. Plumb, Antigen Test Positivity After  
591 COVID-19 Isolation — Yukon-Kuskokwim Delta Region, Alaska, January–February 2022.  
592 *MMWR. Morbidity and Mortality Weekly Report.* **71** (2022), pp. 293–298.
- 593 24. R. Earnest, C. Chen, C. Chaguza, N. D. Grubaugh, M. S. Wilson, Daily Rapid Antigen Test-  
594 ing in a University Setting to Inform COVID-19 Isolation Duration Policy. *medRxiv*,  
595 2022.03.11.22272264 (2022).
- 596 25. A. Singanayagam, M. Patel, A. Charlett, J. L. Bernal, V. Saliba, J. Ellis, S. Ladhani, M.  
597 Zambon, R. Gopal, Duration of infectiousness and correlation with RT-PCR cycle threshold  
598 values in cases of COVID-19, England, January to May 2020. *Eurosurveillance.* **25**,  
599 2001483 (2020).
- 600 26. C. D. Mack, J. DiFiori, C. G. Tai, K. Y. Shiue, Y. H. Grad, D. J. Anderson, D. D. Ho, L.  
601 Sims, C. LeMay, J. Mancell, L. L. Maragakis, SARS-CoV-2 Transmission Risk Among Na-  
602 tional Basketball Association Players, Staff, and Vendors Exposed to Individuals With Posi-  
603 tive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason.  
604 *JAMA Intern. Med.* (2021), doi:10.1001/jamainternmed.2021.2114.
- 605 27. J. Bullard, K. Dust, D. Funk, J. E. Strong, D. Alexander, L. Garnett, C. Boodman, A. Bello,  
606 A. Hedley, Z. Schiffman, K. Doan, N. Bastien, Y. Li, P. G. van Caesele, G. Poliquin, Pre-  
607 dicting infectious SARS-CoV-2 from diagnostic samples. *Clin. Infect. Dis.* **71**, 2663–2666  
608 (2020).
- 609 28. A. Singanayagam, M. Patel, A. Charlett, J. L. Bernal, V. Saliba, J. Ellis, S. Ladhani, M.  
610 Zambon, R. Gopal, Duration of infectiousness and correlation with RT-PCR cycle threshold  
611 values in cases of COVID-19, England, January to May 2020. *Eurosurveillance.* **25**,  
612 2001483 (2020).
- 613 29. R. Jaafar, S. Aherfi, N. Wurtz, C. Grimaldier, T. Van Hoang, P. Colson, D. Raoult, B. La  
614 Scola, Correlation Between 3790 Quantitative Polymerase Chain Reaction–Positives Sam-  
615 ples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coro-  
616 navirus 2 Isolates. *Clinical Infectious Diseases.* **72** (2021), pp. e921–e921.

- 617 30. T. Jefferson, E. A. Spencer, J. Brassey, C. Heneghan, Viral Cultures for Coronavirus Dis-  
618 ease 2019 Infectivity Assessment: A Systematic Review. *Clin. Infect. Dis.* **73**, e3884–e3899  
619 (2020).
- 620 31. G. Pilarowski, T. C. Consortium, P. Lebel, T. C. Consortium, S. Sunshine, T. C. Consor-  
621 tium, J. Liu, T. C. Consortium, E. Crawford, T. C. Consortium, C. Marquez, T. C. Consor-  
622 tium, L. Rubio, T. C. Consortium, G. Chamie, T. C. Consortium, J. Martinez, T. C. Consor-  
623 tium, J. Peng, T. C. Consortium, D. Black, T. C. Consortium, W. Wu, T. C. Consortium, J.  
624 Pak, T. C. Consortium, M. T. Laurie, T. C. Consortium, D. Jones, T. C. Consortium, S. Mil-  
625 ler, T. C. Consortium, J. Jacobo, T. C. Consortium, S. Rojas, T. C. Consortium, S. Rojas, T.  
626 C. Consortium, R. Nakamura, T. C. Consortium, V. Tulier-Laiwa, T. C. Consortium, M. Pe-  
627 tersen, T. C. Consortium, D. V. Havlir, T. C. Consortium, J. DeRisi, T. C. Consortium, Per-  
628 formance Characteristics of a Rapid Severe Acute Respiratory Syndrome Coronavirus 2  
629 Antigen Detection Assay at a Public Plaza Testing Site in San Francisco. *J. Infect. Dis.* **223**,  
630 1139–1144 (2021).
- 631 32. L. Thommes, F. R. Burkert, K. W. Öttl, D. Goldin, L. Loacker, L. Lanser, A. Griesmacher, I.  
632 Theurl, G. Weiss, R. Bellmann-Weiler, Comparative evaluation of four SARS-CoV-2 antigen  
633 tests in hospitalized patients. *Int. J. Infect. Dis.* **105**, 144 (2021).
- 634 33. A. Brihn, J. Chang, K. OYong, S. Balter, D. Terashita, Z. Rubin, N. Yeganeh, Diagnostic  
635 Performance of an Antigen Test with RT-PCR for the Detection of SARS-CoV-2 in a Hospi-  
636 tal Setting — Los Angeles County, California, June–August 2020. *MMWR Morb. Mortal.*  
637 *Wkly. Rep.* **70**, 702–706 (2021).
- 638 34. C. B. F. Vogels, M. I. Breban, I. M. Ott, T. Alpert, M. E. Petrone, A. E. Watkins, C. C. Kali-  
639 nich, R. Earnest, J. E. Rothman, J. G. de Jesus, I. M. Claro, G. M. Ferreira, M. A. E.  
640 Crispim, L. Singh, H. Tegally, U. J. Anyaneji, E. B. Hodcroft, C. E. Mason, G. Khullar, J.  
641 Metti, J. T. Dudley, M. J. MacKay, M. Nash, J. Wang, C. Liu, P. Hui, S. Murphy, C. Neal, E.  
642 Laszlo, M. L. Landry, A. Muyombwe, R. Downing, J. Razeq, T. de Oliveira, N. R. Faria, E.  
643 C. Sabino, R. A. Neher, J. R. Fauver, N. D. Grubaugh, F. C. da Silva Sales, M. S. Ra-  
644 mundo, D. S. Candido, C. A. M. Silva, M. C. de Pinho, T. de M. Coletti, P. dos S. Andrade,  
645 L. M. de Souza, E. C. Rocha, A. C. Gomes Jardim, E. Manuli, N. Gaburo, C. Granato, J. E.  
646 Levi, S. Costa, W. M. de Souza, M. A. Salum, R. Pereira, A. de Souza, L. E. Matkin, M. L.  
647 Nogueira, A. S. Levin, P. Mayaud, N. Alexander, R. Souza, A. L. Acosta, C. Prete, J. Quick,  
648 O. Brady, J. Messina, M. Kraemer, N. da C. Gouveia, I. Oliva, M. de Souza, C. Lazari, C. S.  
649 Alencar, J. Thézé, L. Buss, L. Araujo, M. S. Cunha, N. J. Loman, O. G. Pybus, R. S. Aguiar,  
650 E. Wilkinson, N. Msomi, A. Iranzadeh, V. Fonseca, D. Doolabh, E. J. San, K. Mlisana, A.  
651 von Gottberg, S. Walaza, M. Allam, A. Ismail, T. Mohale, A. J. Glass, S. Engelbrecht, G.  
652 van Zyl, W. Preiser, F. Petruccione, A. Sigal, D. Hardie, G. Marais, M. Hsiao, S. Korsman,  
653 M. A. Davies, L. Tyers, I. Mudau, D. York, C. Maslo, D. Goedhals, S. Abrahams, O.  
654 Laguda-Akingba, A. Alisoltani-Dehkordi, A. Godzik, C. K. Wibmer, B. T. Sewell, J. Lou-  
655 renço, S. L. Kosakovsky Pond, S. Weaver, M. Giovanetti, L. C. J. Alcantara, D. Martin, J. N.  
656 Bhiman, C. Williamson, Multiplex qPCR discriminates variants of concern to enhance global  
657 surveillance of SARS-CoV-2. *PLoS Biol.* **19**, e3001236 (2021).
- 658 35. BaseSpace Labs. DRAGEN COVID Lineage (2021).
- 659 36. A. Rambaut, E. C. Holmes, Á. O’Toole, V. Hill, J. T. McCrone, C. Ruis, L. du Plessis, O. G.  
660 Pybus, A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epi-  
661 demiology. *Nature Microbiology* 2020 5:11. **5**, 1403–1407 (2020).

- 662 37. I. Aksamentov, R. Neher, NextClade (2021).
- 663 38. P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P. D.  
664 Kwong, B. S. Graham, J. R. Mascola, J. Y. Chang, M. T. Yin, M. Sobieszczyk, C. A.  
665 Kyratsous, L. Shapiro, Z. Sheng, Y. Huang, D. D. Ho, Antibody resistance of SARS-CoV-2  
666 variants B.1.351 and B.1.1.7. *Nature*. **593**, 130–135 (2021).
- 667 39. L. Liu, S. Iketani, Y. Guo, J. F.-W. Chan, M. Wang, L. Liu, Y. Luo, H. Chu, Y. Huang, M. S.  
668 Nair, J. Yu, K. K.-H. Chik, T. T.-T. Yuen, C. Yoon, K. K.-W. To, H. Chen, M. T. Yin, M. E.  
669 Sobieszczyk, Y. Huang, H. H. Wang, Z. Sheng, K.-Y. Yuen, D. D. Ho, Striking antibody  
670 evasion manifested by the Omicron variant of SARS-CoV-2. *Nature*. **602**, 676–681 (2021).
- 671 40. D. S. Khoury, D. Cromer, A. Reynaldi, T. E. Schlub, A. K. Wheatley, J. A. Juno, K. Sub-  
672 barao, S. J. Kent, J. A. Triccas, M. P. Davenport, Neutralizing antibody levels are highly  
673 predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat. Med.* **27**,  
674 1205–1211 (2021).
- 675 41. Bürkner, brms: An R package for Bayesian multilevel models using Stan. *J. Stat. Softw.*  
676 (available at <http://138.232.16.156/article/view/v080i01>).